The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MDS 2021 | ESA and other growth factors for MDS
With anemia and transfusion dependence representing a large burden on quality of life (QoL), it’s not a surprise erythropoietic growth factors (ESAs) are being used for lower-risk myelodysplastic syndrome (MDS) in many countries. In this video, Valeria Santini, MD, University of Florence, Florence, Italy, discusses erythropoietin-stimulating agents (ESAs) and other growth factors for myelodysplastic syndromes (MDS). This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.
